PET/CT in prostate cancer influences staging, treatment strategy

November 30, 2008 DiagnosticImaging.com. PET/CT in prostate cancer influences staging, treatment strategy By Shalmali Pal Prostate-specific antigen measurements are considered a useful organ-specific marker, but they are not necessarily an adequate tumor marker. PET/CT in combination with PSA levels can play a significant role in detecting and staging prostate cancer, according to two presentations Sunday at RSNA 2008. Dr. Nghi Nguyen presented his multi-institutional group's work on the utility of PET/CT in staging and restaging prostate cancer. Nguyen is from St. Louis University Hospital, where the research was conducted. The study's lead author, Dr. Kahlid Taalab Jr., is now based in Cairo.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC